Get started
Author

Sandra Irenaeus

Observed names: Irenaeus, Sandra, S. Irenaeus, Sandra M. M. Irenaeus
ORCID: 0000-0002-2107-7512
Observed ORCID: 0000-0002-2107-7512
OpenAlex ID: A5042324852
Gemcitabine reduces MDSCs, tregs and TGFβ-1 while restoring the teff/treg ratio in patients with pancreatic cancer
2016 · Emma Eriksson, Jessica Wenthe, et al. · Journal of Translational Medicine · 219
PDF
First‐in‐human study with intratumoral administration of a CD40 agonistic antibody, ADC‐1013, in advanced solid malignancies
2019 · Sandra M. M. Irenaeus, Dorte Nielsen, et al. · International Journal of Cancer · 133
Development and validation of a multi-dimensional diagnosis-based comorbidity index that improves prediction of death in men with prostate cancer: Nationwide, population-based register study
2024 · Marcus Westerberg, Sandra Irenaeus, et al. · PLoS ONE · 26
Evaluation of Diffusion-Weighted MRI and FDG-PET/CT to Assess Response to AdCD40L treatment in Metastatic Melanoma Patients
2019 · Aglaia Schiza, Sandra Irenaeus, et al. · Scientific Reports · 11
PDF
Intratumoral immunostimulatory AdCD40L gene therapy in patients with advanced solid tumors
2020 · Sandra Irenaeus, Vivan Hellström, et al. · Cancer Gene Therapy · 10
Changes in cancer incidence and stage during the COVID-19 pandemic in 2020–2021 in the Nordic countries
2025 · Anna Johansson, Anna Skog, et al. · Acta Oncologica · 9
PDF
Effect of alcohol consumption on oncological treatment effectiveness and toxicity in patients with cancer: a systematic review and meta-analysis
2025 · Georgios Fountoukidis, Aglaia Schiza, et al. · BMC Cancer · 8
PDF
Were cancer patients worse off than the general population during the COVID-19 pandemic? A population-based study from Norway, Denmark and Iceland during the pre-vaccination era
2023 · Anna L.V. Johansson, Anna Skog, et al. · The Lancet Regional Health - Europe · 7
Local irradiation does not enhance the effect of immunostimulatory AdCD40L gene therapy combined with low dose cyclophosphamide in melanoma patients
2017 · Sandra Irenaeus, Aglaia Schiza, et al. · Oncotarget · 5
PDF
Choice of imputation method for missing metastatic status affected estimates of metastatic prostate cancer incidence
2022 · Marcus Westerberg, Kerri Beckmann, et al. · Journal of Clinical Epidemiology · 4
PDF
Abstract PO-018: Inflaming advanced solid tumors including pancreatic cancer using LOAd703, a TMZ-CD40L/4-1BBL-armed oncolytic virus
2021 · Jessica Wenthe, Emma Eriksson, et al. · Cancer Research · 4
LOAd703-induced tumor microenvironment gene engineering in combination with atezolizumab in metastatic malignant melanoma: a phase I/II trial
2026 · O. Hamid, V. Ekström-Rydén, et al. · Nature Communications · 3
PDF
Tumor Microenvironment Gene Engineering with LOAd703 in Patients with Solid Malignancies: LOKON002 Phase I/IIb Clinical Trial
2026 · Amanda Hahn, Sandra Irenaeus, et al. · Clinical Cancer Research · 1
Abstract CT235: A phase I/II clinical study of an oncolytic adenovirus expressing the immunostimulatory transgenes TMZ-CD40L and 4-1BBL in advanced solid malignancies
2023 · Amanda Hahn, Sandra Irenaeus, et al. · Cancer Research · 1
Abstract 6663: Immunostimulatory gene therapy targeting CD40/4-1BB in combination with chemotherapy induces an inflammatory gene profile in tumors from patients with advanced disease
2023 · Jessica Wenthe, Emma Eriksson, et al. · Cancer Research · 1
Supplementary Table S3 from Tumor Microenvironment Gene Engineering with LOAd703 in Patients with Solid Malignancies: LOKON002 Phase I/IIb Clinical Trial
2026 · Amanda Hahn, Sandra Irenaeus, et al.
Supplementary Table S2 from Tumor Microenvironment Gene Engineering with LOAd703 in Patients with Solid Malignancies: LOKON002 Phase I/IIb Clinical Trial
2026 · Amanda Hahn, Sandra Irenaeus, et al.
Supplementary Data S1 from Tumor Microenvironment Gene Engineering with LOAd703 in Patients with Solid Malignancies: LOKON002 Phase I/IIb Clinical Trial
2026 · Amanda Hahn, Sandra Irenaeus, et al.
Supplementary Table S1 from Tumor Microenvironment Gene Engineering with LOAd703 in Patients with Solid Malignancies: LOKON002 Phase I/IIb Clinical Trial
2026 · Amanda Hahn, Sandra Irenaeus, et al.
Supplementary Figure S1 from Tumor Microenvironment Gene Engineering with LOAd703 in Patients with Solid Malignancies: LOKON002 Phase I/IIb Clinical Trial
2026 · Amanda Hahn, Sandra Irenaeus, et al.
Data from Tumor Microenvironment Gene Engineering with LOAd703 in Patients with Solid Malignancies: LOKON002 Phase I/IIb Clinical Trial
2026 · Amanda Hahn, Sandra Irenaeus, et al.
Supplementary Figure S2 from Tumor Microenvironment Gene Engineering with LOAd703 in Patients with Solid Malignancies: LOKON002 Phase I/IIb Clinical Trial
2026 · Amanda Hahn, Sandra Irenaeus, et al.
Safety of intratumoral immunostimulatory LOAd703 gene therapy combined with chemotherapy in patients with advanced cancer
2026 · A. Hahn, S. Irenaeus, et al. · Immuno-Oncology Technology
Potential gains from radical treatment of men with prostate cancer according to life expectancy
2025 · Sandra Irenaeus, Hans Garmo, et al. · BJUI Compass
PDF
989O Novel gene therapy in advanced solid malignancies: A phase I/II clinical trial
2024 · L. Hahn, S. Irenaeus, et al. · Annals of Oncology
PDF
Works count: 34
Citation count: 442
H-index: 7
I10-index: 5
Year
Topic
Type